PO.CL05.07 · 临床研究
整合空间单细胞蛋白质组学与空间代谢组学揭示可预测黏膜黑色素瘤免疫治疗应答的肿瘤微环境
Integration of spatial single cell proteomics and spatial metabolomics reveals tumor microenvironment predictive of immunotherapy response in mucosal melanoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:黏膜黑色素瘤(MuM)是一种罕见的黑色素瘤亚型,仅占所有黑色素瘤病例的1-2%,但其高度侵袭性,对免疫检查点阻断的应答性较更常见的皮肤黑色素瘤更差。然而,驱动MuM治疗耐药的生物学机制仍知之甚少。本研究旨在揭示MuM对免疫检查点阻断治疗应答和耐药的空间及分子机制。
研究设计与方法:应用了一个整合的空间多组学框架,将使用COMET平台的单细胞空间蛋白质组学与使用成像质谱(MALDI-IMS)的高质量分辨率空间代谢组学相结合。我们对来自26例接受PD-1/PD-L1或CTLA-4抑制剂治疗的MuM患者的97个FFPE组织芯进行了全面分析,刻画了细胞组成和空间定义的细胞邻域(CN)。进一步在应答者和无应答者之间比较了CN的空间组织、细胞-细胞相互作用、蛋白质组学谱和代谢组学特征。
结果:该综合方法实现了对695,444个单细胞的空间分辨分析,这些细胞被归类为跨越9个主要细胞谱系的25种细胞表型。空间细胞邻域分析揭示了15个生物学上不同的CN,它们在肿瘤、免疫和间质细胞区室的组成及空间分布上存在差异。在对免疫治疗应答的患者中,三个肿瘤相关CN——中央肿瘤、侵袭性肿瘤和肿瘤边界CN——显著富集,并共同形成独特的空间组织模式。值得注意的是,侵袭性肿瘤CN和肿瘤边界CN以Ki67⁺肿瘤细胞、CD163⁺巨噬细胞和CD11c⁺树突状细胞之间的空间邻近为特征。这些CD163⁺巨噬细胞表现出IRF4和Arg1表达降低,与较低的免疫抑制活性一致。相反,无应答者表现出以SMA⁻间质细胞为主构成的间质主导型CN,并在治疗前和治疗后样本中均表现出免疫浸润减少。空间代谢组学分析进一步揭示应答者中色氨酸衍生的吲哚代谢物显著减少,这与CD11c和CD163表达显著相关,表明肿瘤微环境内存在协调的免疫代谢重塑。
结论:这些发现凸显了空间肿瘤-免疫结构、间质排斥和代谢重编程共同塑造了MuM的免疫治疗应答。所识别的空间分辨的色氨酸衍生代谢物特征提供了有前景的生物标志物和潜在治疗靶点,以改善这一临床上具有挑战性的黑色素瘤亚型的治疗结局。
查看英文原文 English abstract
Background: Mucosal melanoma (MuM) is a rare melanoma subtype, accounting for only 1-2% of all melanoma cases, yet is highly aggressive, demonstrating poorer responsiveness to immune checkpoint blockade than the more common cutaneous melanoma. However, the biological mechanisms driving therapeutic resistance in MuM remain poorly understood. This study aims to uncover spatial and molecular mechanisms underlying response and resistance of MuM to immune checkpoint blockade therapies.
Study Design and Methods: An integrative spatial multi-omics framework was applied, which combined single-cell spatial proteomics using COMET platform with high mass resolution spatial metabolomics using imaging mass spectrometry (MALDI-IMS). We comprehensively profiled cellular compositions and spatially defined cellular neighborhoods (CNs) across 97 FFPE tissue cores from 26 MuM patients treated with PD-1/PD-L1 or CTLA-4 inhibitors. Spatial organization, cell-cell interactions, proteomic profiles and metabolomic features of CNs were further compared across responders and non-responders.
Results: The comprehensive approach enabled spatially resolved profiling of 695,444 single cells, which were categorized into 25 cellular phenotypes spanning 9 major cell lineages. Spatial cellar neighborhood analysis revealed 15 biologically distinct CNs that differed in their composition and spatial distribution of tumor, immune, and stromal cell compartments. In patients who responded to immunotherapy, three tumor-associated CNs-the central tumor, invasive tumor, and tumor boundary CNs-were significantly enriched and collectively formed unique spatial organization patterns. Notably, the invasive tumor CN and tumor boundary CN were characterized by spatial proximity among Ki67⁺ tumor cells, CD163⁺ macrophages, and CD11c⁺ dendritic cells. These CD163⁺ macrophages exhibited reduced expression of IRF4 and Arg1, consistent with lower immunosuppressive activity. Conversely, non-responders exhibited a stromal-dominant CN composed primarily of SMA - stromal cells and demonstrated reduced immune infiltration in both pre-treatment and post-treatment samples. Spatial metabolomic profiling further revealed a pronounced reduction of tryptophan-derived indole metabolites in responders, which significantly correlated with CD11c and CD163 expression, indicating coordinated immunometabolic remodeling within the tumor microenvironment.
Conclusions: These findings highlight that spatial tumor-immune architecture, stromal exclusion, and metabolic rewiring collectively shape immunotherapy response in MuM. The identified spatially resolved tryptophan-derived metabolite signatures offer promising biomarkers and potential therapeutic targets to improve treatment outcomes in this clinically challenging melanoma subtype.
利益披露 Disclosure
J. Wang, None..
P. Nagarajan, None..
S. Cho, None..
Y. Liu, None..
E. H. Seeley, None..
Y. Dai, None..
Y. Liu, None..
J. K. Burks, None..
J. L. McQuade, None..
A. Diab, None..
L. Wang, None..
S. Ekmekcioglu, None.